Unicycive Therapeutics (UNCY) Share-based Compensation (2020 - 2026)

Unicycive Therapeutics (UNCY) has reported Share-based Compensation for 7 consecutive years, with $2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 102.57% year-over-year to $2.9 million; the trailing twelve-month figure through Jun 2026 stood at $4.8 million (up 236.94% YoY), and the FY2025 full-year result was $5.6 million, up 1.82% from the prior year.
• Share-based Compensation rose to $2.9 million in Q2 2026 per UNCY's latest filing, from $2.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $161.0 million in Q2 2023 and bottomed at $144000.0 in Q1 2023.
• Historically, Share-based Compensation has averaged $21.4 million across 5 years, with a median of $1.7 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation soared 60410.59% in 2023, then sank 91.87% in 2024.
• Over 5 years, Share-based Compensation stood at $197000.0 in 2022, then surged by 179.19% to $550000.0 in 2023, then advanced by 5.82% to $582000.0 in 2024, then soared by 33.51% to $777000.0 in 2025, then soared by 270.4% to $2.9 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2.9 million, $2.2 million, and $777000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.